Arca
Skip to content
Tools
Tools

IFNGR1, IFNGR2: Interferon gamma receptor

Complex in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on IFNGR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1

Approved1

  • Interferon gamma-1b

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        Interferon gamma-1bApprovedAmgenProtein or peptideAgonistInterferon gamma receptor agonist32

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaInterferon gamma-1bPhase 2RecruitingHefei Cancer Hospital of the Chinese Academy of SciencesAug 26, 2026
        Incidence of Tuberculosis in Patients With Autoimmune Rheumatic DiseasesInterferon gamma-1bNot applicableNot yet recruitingUniversity of Sao Paulo General HospitalJul 28, 2026
        Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANSInterferon gamma-1bPhase 2Not yet recruitingNYU Langone HealthMay 5, 2026
        Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft DysfunctionInterferon gamma-1bPhase 2Not yet recruitingUniversity of California, San FranciscoApr 20, 2026
        Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) RecipientsInterferon gamma-1bEarly phase 1RecruitingChildren's Hospital Medical Center, CincinnatiNov 24, 2025
        Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantInterferon gamma-1bPhase 1RecruitingCity of Hope Medical CenterMay 30, 2025
        Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised ImmunityInterferon gamma-1bPhase 1 / Phase 2RecruitingJessie L. AlexanderApr 3, 2025
        Clinical Usefulness of a Multi-analyte Immunoassay for Distinguishing Bacterial and Viral Infections in ChildrenInterferon gamma-1bNot applicableActive, not recruitingMeyer Children's Hospital IRCCSFeb 28, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364171, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.